Main description:

A broad and experienced team, including medical oncologists and life scientists, have collaborated to produce this practical guide to cancer immunotherapy. It provides a compendium of best practice, including 23 case studies to act as models for professionals to make decisions, either for individual patients or as the basis for using immunotherapy across an organisation, planning area, region or country. As well as introducing all key concepts, expert practitioners provide a guide to future treatments using novel technologies, discuss key problems and suggest solutions, and consider the costs of immunotherapy treatments.This guide also makes an excellent training tool, which will help new teams and clinical staff to develop procedures, and adopt best practice.

This resource is produced in partnership with the Association of Cancer Physicians (ACP).

Contents:

1) Immunotherapy - past, present and future; 2) Beyond exhausted. Tumour immune checkpoints and their therapeutic targets; 3) Checkpoint inhibitors: where have we come from and where are we going?; 4) Immune-related toxicity of checkpoint inhibitors; 5) Predicting response to immunotherapy; 6) Difficulties in assessment of PD-L1 expression; 7) Radiological assessment of immunotherapy; 8) Combination immunotherapies - multimodality treatment; 9) The future of novel vaccine strategies in cancer immunotherapy; 10) Genetically modified cell therapy for solid tumours; 11) Adoptive cell therapy for haematological malignancies; 12) Tumour infiltrating lymphocytes (TILs).
Case Studies: 1) A case of cytokine release syndrome; 2) High Dose Interleukin- 2 Induced Myocarditis; 3) Multiorgan toxicity following combination immunotherapy in melanoma; 4) Immune-related Endocrine Toxicity Following Immune Checkpoint Inhibitor Therapy; 5) Checkpoint Inhibitors in patients with autoimmune disease; 6) A patient with Lung Cancer who received an immune checkpoint inhibitor in the first-line setting; 7) A Case of Sinonasal Mucosal Melanoma; 8) Adjuvant immunotherapy in metastatic melanoma; 9) Ongoing response after stopping immunotherapy; 10) A case of pneumonitis following treatment with an anti-PD1 antibody in a patient with NSCLC; 11) A case of colitis following combination immunotherapy within a clinical study for Small Cell Lung cancer; 12) Jaundice after pembrolizumab in a patient with melanoma and brain metastases; 13) Localised scleroderma as a manifestation of a skin immune-related adverse event in a patient with metastatic melanoma treated with pembrolizumab; 14) Intracranial melanoma response to Combination Ipilimumab and Nivolumab; 15) A case of delayed response to immunotherapy in a patient with acral melanoma; 16) A Case of Facial Nerve Palsy in a Patient with Renal Cell Carcinoma Treated with Nivolumab; 17) A Case of Acute Kidney Injury in a Patient on Combination Immunotherapy for Metastatic Melanoma; 18) Merkels cell cancer receiving immunotherapy; 19) A Case of Immune Pneumonitis Following Immunotherapy for Metastatic Melanoma; 20) Patient with ureteric TCC on anti-PD1 antibody - complicated by sarcoidosis; 21) A case of renal cell carcinoma treated with ipilimumab and nivolumab; 22) A case of ocular toxicity from Nivolumab; 23) A case of multiple immune related toxicities in a patient with breast cancer on a checkpoint inhibitor and chemotherapy; 24) Oncolytic viral therapy: T-VEC